The EMA and the FDA have both agreed to a Phase III randomized placebo-controlled study with nomacopan in moderate to severe bullous pemphigoid (BP) patients …

[Read more...] about Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid

NEW YORK and LONDON, September 10, 2020 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …

[Read more...] about Akari Therapeutics to Participate in Two September Virtual Investor Conferences